| NCT ID | NCT05835791 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nova Scotia Health Authority |
| Condition | Ventricular Tachycardia |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,454 participants |
| Start Date | 2024-01-12 |
| Primary Completion | 2028-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,454 participants in total. It began in 2024-01-12 with a primary completion date of 2028-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ventricular tachycardia (VT) is a life-threatening cardiac rhythm disturbance which leads to sudden cardiac death (SCD), ventricular fibrillation, electrical storm, hemodynamic collapse, and syncope. VT patients with cardiomyopathy (diseased/scarred cardiac muscle) have the highest risk of SCD (\<1-4%) and recurrent VTs (15-35%). Although an implantable cardiac defibrillator (ICD) is the most effective treatment option to prevent SCD, it does not eliminate it. Without VT prevention, recurrent VT and ICD shocks may increase the risk of heart failure and death. The primary objective is to determine the optimal treatment strategy to maximize event-free survival among cardiomyopathy patients with ventricular tachycardia (VT) by the creation of a prospective, multicenter, longitudinal cohort. Also, the investigators will evaluate the epidemiology of VT, adherence to guidelines, safety, effectiveness, and cost-effectiveness of current treatment options for secondary prevention of VT in the real-world Canadian VT population.
Eligibility Criteria
Inclusion Criteria: 1. Documented sustained ventricular arrhythmia (\>30 seconds as documented by an ECG, cardiac monitor, AED, and/or intracardiac pacemaker/ICD electrograms (EGMs); 2. First (new) diagnosis of VT; 3. Presence of or plan for ICD implant during index hospitalization; 4. Diagnosis of cardiomyopathy (ie. ICM, hypertrophic, dilated, restrictive, arrhythmogenic cardiomyopathy, or other scar), 5. ICD clinic follow-up planned, and 6. Age \>18 years old Exclusion Criteria: 1\) Patients with VT due to a reversible cause
Contact & Investigator
Michelle Samuel, MPH, PhD
PRINCIPAL INVESTIGATOR
Montreal Heart Institute
Frequently Asked Questions
Who can join the NCT05835791 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ventricular Tachycardia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05835791 currently recruiting?
Yes, NCT05835791 is actively recruiting participants. Contact the research team at john.sapp@nshealth.ca for enrollment information.
Where is the NCT05835791 trial being conducted?
This trial is being conducted at Vancouver, Canada, Halifax, Canada, Montreal, Canada.
Who is sponsoring the NCT05835791 clinical trial?
NCT05835791 is sponsored by Nova Scotia Health Authority. The principal investigator is Michelle Samuel, MPH, PhD at Montreal Heart Institute. The trial plans to enroll 2,454 participants.